Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15,293 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.
Kudo M, Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Akazawa K, Yoshimura KI, Johnson P, Arai Y; SILIUS study group. Kudo M, et al. Among authors: yamamoto k. Lancet Gastroenterol Hepatol. 2018 Jun;3(6):424-432. doi: 10.1016/S2468-1253(18)30078-5. Epub 2018 Apr 7. Lancet Gastroenterol Hepatol. 2018. PMID: 29631810 Clinical Trial.
Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B.
Kobashi H, Fujioka S, Kawaguchi M, Kumada H, Yokosuka O, Hayashi N, Suzuki K, Okanoue T, Sata M, Tsubouchi H, Sato C, Kiyosawa K, Tanikawa K, Seriu T, Ishikawa H, Takaki A, Iwasaki Y, Osawa T, Takaki T, Sakaguchi K, Shiratori Y, Yamamoto K, Tenney DJ, Omata M. Kobashi H, et al. Among authors: yamamoto k. Hepatol Int. 2009 Jun;3(2):403-10. doi: 10.1007/s12072-008-9108-8. Epub 2008 Dec 9. Hepatol Int. 2009. PMID: 19669367 Free PMC article.
Application of radiofrequency ablation for the treatment of metastatic liver cancers.
Nouso K, Kobayashi Y, Nakamura S, Uematsu S, Shiraga K, Iwadou S, Araki Y, Taniguchi H, Tanaka H, Toshikuni N, Kaneyoshi T, Ikeda H, Fujioka S, Osawa T, Iwasaki Y, Shiraha H, Yamamoto K. Nouso K, et al. Among authors: yamamoto k. Hepatogastroenterology. 2010 Jan-Feb;57(97):117-20. Hepatogastroenterology. 2010. PMID: 20422885
Prognostic model for hepatocellular carcinoma with time-dependent factors.
Kuwaki K, Nouso K, Kobayashi Y, Nakamura S, Ito YM, Iwadou S, Hagihara H, Yasunaka T, Toshimori J, Miyatake H, Miyoshi K, Onishi H, Miyake Y, Shoji B, Takaki A, Shiraha H, Iwasaki Y, Kobashi H, Yamamoto K. Kuwaki K, et al. Among authors: yamamoto k. Acta Med Okayama. 2011 Feb;65(1):11-9. doi: 10.18926/AMO/43825. Acta Med Okayama. 2011. PMID: 21339791 Free article.
Prognostic importance of fucosylated alpha-fetoprotein in hepatocellular carcinoma patients with low alpha-fetoprotein.
Nouso K, Kobayashi Y, Nakamura S, Kobayashi S, Takayama H, Toshimori J, Kuwaki K, Hagihara H, Onishi H, Miyake Y, Ikeda F, Shiraha H, Takaki A, Iwasaki Y, Kobashi H, Yamamoto K. Nouso K, et al. Among authors: yamamoto k. J Gastroenterol Hepatol. 2011 Jul;26(7):1195-200. doi: 10.1111/j.1440-1746.2011.06720.x. J Gastroenterol Hepatol. 2011. PMID: 21410750
A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II study to evaluate toxicity and dose intensity.
Hirao K, Kawamoto H, Sakakihara I, Noma Y, Yamamoto N, Harada R, Tsutsumi K, Fujii M, Kato H, Kurihara N, Mizuno O, Ogawa T, Ishida E, Yamamoto K. Hirao K, et al. Among authors: yamamoto n, yamamoto k. Int J Clin Oncol. 2011 Dec;16(6):637-45. doi: 10.1007/s10147-011-0237-z. Epub 2011 Apr 26. Int J Clin Oncol. 2011. PMID: 21519814 Clinical Trial.
15,293 results
You have reached the last available page of results. Please see the User Guide for more information.